EPIDUO GEL Rx
Generic Name and Formulations:
Adapalene 0.1%, benzoyl peroxide 2.5%; gel.
Galderma Laboratories, Inc.
Indications for EPIDUO GEL:
Treatment of acne vulgaris in patients ≥9 years of age.
Adults and Children:
<9yrs: not established. ≥9yrs: apply thin film to affected areas of face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (eg, forehead, chin, cheek). Reduce frequency or discontinue if prolonged or severe irritation occurs.
Do not use on cuts, abrasions, eczematous or sunburned skin. Avoid eyes, lips, mucous membranes, sun, UV light. Increased irritation in extreme weather. Pregnancy (Cat.C). Nursing mothers.
Retinoid + antibacterial/keratolytic.
Caution with other topical acne therapy (eg, peeling, desquamating, or abrasive agents). Avoid using concomitant topical irritants and waxing treated areas.
Dry skin, contact dermatitis, skin irritation, eczema; local reactions (eg, erythema, scaling, dryness, burning, stinging), may bleach fabrics or hair.
Adapalene: biliary. Benzoyl peroxide: renal.
Gel—45g (tube or pump); Forte Gel—15g, 30g, 45g, 60g, 70g pump
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC